January
23, 2019, Philadelphia, PA – Talee Bio, Inc., a development stage
biopharmaceutical company focused on developing gene therapy treatments for
cystic fibrosis, today announced agreements with the Cystic Fibrosis Foundation
(CF Foundation) to fund the preclinical development of two mutation-agnostic
gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed
up to $4.5 million to expedite the development of both product candidates for
all people with cystic fibrosis, and particularly those individuals with no
viable treatment options for the underlying cause of the disease.
TL-101
is an aerosolized, recombinant AAV product candidate to treat pulmonary
manifestations of cystic fibrosis of through single or multiple doses. TL-101
is currently in preclinical development with a goal of initiating clinical
trials in 2020. TL-102 is an aerosolized lentiviral product candidate with the
potential to cure pulmonary manifestations of cystic fibrosis after one dose.
Each of these product candidates is the result of decades of research by
world-class academic experts developing innovations that overcome historical
hurdles to achieving meaningful efficacy in diseased lung.
“We
are delighted that the Cystic Fibrosis Foundation is continuing to support the
development of these gene therapy product candidates,” commented Joan Lau, CEO
of Talee Bio. She continued, “Gene therapy treatments offer great
potential to treat all patients with CF, including those with nonsense mutations
and no available treatment options. We are honored to be working with the CF
Foundation to expedite the development of these important development products
in order to improve and extend the lives of every CF patient.”
About
Cystic Fibrosis
Cystic
Fibrosis (CF) is a progressive, life-threatening genetic disorder affecting the
lungs and digestive system that impacts more than 75,000 worldwide. CF is
characterized by thickened mucus and inflammation, especially in the airways,
leading to chronic infections and progressively worsening ability to breathe.
CF is caused by mutations in the CFTR gene, an ion channel whose malfunction
causes the thickening of mucus. Currently, the disease has no cure and leads to
premature death at an average age of 39 years.
About
Talee Bio
Talee
Bio is a development stage biopharmaceutical company focused on developing gene
therapy products for the treatment of cystic fibrosis. The company is
developing two inhaled gene therapy drug candidates to treat all cystic
fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a
lentivirus gene therapy. The company was founded by world-class academic
researchers from the University of Iowa and the Children’s Hospital of
Philadelphia and Militia Hill Ventures, an active-build
venture capital firm based in Philadelphia, with support from Emily’s
Entourage.
Contact: Joan Lau, PhD |
CEO, Talee Bio, Inc. | [email protected]
